Abiraterone
The serum concentration of Carteolol can be increased when it is combined with Abiraterone.
Acebutolol
Carteolol may increase the hypotensive activities of Acebutolol.
Aceclofenac
Aceclofenac may decrease the antihypertensive activities of Carteolol.
Advertisement
Acemetacin
The therapeutic efficacy of Carteolol can be decreased when used in combination with Acemetacin.
Acepromazine
Carteolol may increase the orthostatic hypotensive activities of Acepromazine.
Aceprometazine
Aceprometazine may increase the hypotensive activities of Carteolol.
Advertisement
Acetohexamide
Carteolol may increase the hypoglycemic activities of Acetohexamide.
Acetyl salicylate
Acetylsalicylic acid may decrease the antihypertensive activities of Carteolol.
Acetylcholine
The risk or severity of adverse effects can be increased when Carteolol is combined with Acetylcholine.
Advertisement
Acetylcholine Chloride
The risk or severity of adverse effects can be increased when Carteolol is combined with Acetylcholine.
Acetyldigitoxin
Carteolol may increase the bradycardic activities of Acetyldigitoxin.
Adapalene
Adapalene may decrease the antihypertensive activities of Carteolol.
Albuterol
Carteolol may decrease the bronchodilatory activities of Salbutamol.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carteolol.
Alfentanil
Alfentanil may increase the bradycardic activities of Carteolol.
Alfuzosin
Alfuzosin may increase the hypotensive activities of Carteolol.
Aliskiren
Carteolol may increase the hypotensive activities of Aliskiren.
Alminoprofen
Alminoprofen may decrease the antihypertensive activities of Carteolol.
Alprenolol
Carteolol may increase the hypotensive activities of Alprenolol.
Ambenonium
Ambenonium may increase the bradycardic activities of Carteolol.
Ambrisentan
Carteolol may increase the hypotensive activities of Ambrisentan.
AMBROXOL ACEFYLLINATE
Carteolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.
Ambroxol-Theophylline-7-Acetate
Carteolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.
Amifostine
Carteolol may increase the hypotensive activities of Amifostine.
Amifostine Anhydrous
Carteolol may increase the hypotensive activities of Amifostine.
Amiloride
The risk or severity of adverse effects can be increased when Carteolol is combined with Amiloride.
Aminophylline
Carteolol may decrease the bronchodilatory activities of Aminophylline.
Amiodarone
The therapeutic efficacy of Carteolol can be increased when used in combination with Amiodarone.
Amitriptyline
Carteolol may increase the orthostatic hypotensive activities of Amitriptyline.
Amlodipine
Amlodipine may increase the hypotensive activities of Carteolol.
Amobarbital
The serum concentration of Carteolol can be decreased when it is combined with Amobarbital.
Amodiaquine
The metabolism of Carteolol can be decreased when combined with Amodiaquine.
Amoxapine
Carteolol may increase the orthostatic hypotensive activities of Amoxapine.
Amphetamine
Amphetamine may increase the hypotensive activities of Carteolol.
Amphotericin B
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Carteolol.
amphotericin B liposomal
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Carteolol.
Amyl Nitrite
The risk or severity of adverse effects can be increased when Carteolol is combined with Amyl Nitrite.
Antipyrine
Antipyrine may decrease the antihypertensive activities of Carteolol.
Apazone
Azapropazone may decrease the antihypertensive activities of Carteolol.
Apomorphine
Apomorphine may increase the atrioventricular blocking (AV block) activities of Carteolol.
Apraclonidine
The risk or severity of adverse effects can be increased when Carteolol is combined with Apraclonidine.
Apremilast
Apremilast may decrease the antihypertensive activities of Carteolol.
Arbutamine
Carteolol may decrease the bronchodilatory activities of Arbutamine.
Arformoterol
Carteolol may decrease the bronchodilatory activities of Arformoterol.
Aripiprazole
Aripiprazole may increase the hypotensive activities of Carteolol.
Arsenic Trioxide
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Carteolol.
Artemether
The metabolism of Carteolol can be decreased when combined with Artemether.
Asenapine
Carteolol may increase the orthostatic hypotensive activities of Asenapine.
Aspirin
Acetylsalicylic acid may decrease the antihypertensive activities of Carteolol.
Atenolol
Atenolol may increase the hypotensive activities of Carteolol.
Atomoxetine
The metabolism of Carteolol can be decreased when combined with Atomoxetine.
Avanafil
Avanafil may increase the antihypertensive activities of Carteolol.
Azelastine
Azelastine may decrease the antihypertensive activities of Carteolol.
Azilsartan
The risk or severity of adverse effects can be increased when Carteolol is combined with Azilsartan medoxomil.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Carteolol is combined with Azilsartan medoxomil.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Carteolol is combined with Azilsartan medoxomil.
Balsalazide
Balsalazide may decrease the antihypertensive activities of Carteolol.
Bambuterol
Carteolol may decrease the bronchodilatory activities of Bambuterol.
Barbexaclone
The serum concentration of Carteolol can be decreased when it is combined with Barbexaclone.
Barbital
The serum concentration of Carteolol can be decreased when it is combined with Barbital.
Benazepril
Carteolol may increase the hypotensive activities of Benazepril.
Bendroflumethiazide
Bendroflumethiazide may increase the hypotensive activities of Carteolol.
Benzphetamine
Benzphetamine may increase the atrioventricular blocking (AV block) activities of Carteolol.
Benzydamine
Benzydamine may decrease the antihypertensive activities of Carteolol.
Bepridil
Carteolol may increase the hypotensive activities of Bepridil.
Beractant
Carteolol may increase the bradycardic activities of Beractant.
Betaxolol
The metabolism of Carteolol can be decreased when combined with Betaxolol.
Bethanechol
The risk or severity of adverse effects can be increased when Carteolol is combined with Bethanechol.
Bethanidine
Bethanidine may increase the atrioventricular blocking (AV block) activities of Carteolol.
Bimatoprost
Carteolol may increase the hypotensive activities of Bimatoprost.
Bisoprolol
Carteolol may increase the hypotensive activities of Bisoprolol.
Bitolterol
Carteolol may decrease the bronchodilatory activities of Bitolterol.
Bitolterol Mesylate
Carteolol may decrease the bronchodilatory activities of Bitolterol.
Bortezomib
The risk or severity of adverse effects can be increased when Bortezomib is combined with Carteolol.
Bosentan
Bosentan may increase the hypotensive activities of Carteolol.
Bosentan Anhydrous
Bosentan may increase the hypotensive activities of Carteolol.
Bretylium
Bretylium may increase the bradycardic activities of Carteolol.
Brexpiprazole
Carteolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Brimonidine
Brimonidine may increase the antihypertensive activities of Carteolol.
Bromfenac
Bromfenac may decrease the antihypertensive activities of Carteolol.
Bromocriptine
Bromocriptine may increase the atrioventricular blocking (AV block) activities of Carteolol.
Bufexamac
Bufexamac may decrease the antihypertensive activities of Carteolol.
Bumetanide
The risk or severity of adverse effects can be increased when Carteolol is combined with Bumetanide.
Bunazosin
Carteolol may increase the orthostatic hypotensive activities of Bunazosin.
Bupivacaine
The serum concentration of Bupivacaine can be increased when it is combined with Carteolol.
Bupranolol
Carteolol may increase the hypotensive activities of Bupranolol.
Bupropion
The metabolism of Carteolol can be decreased when combined with Bupropion.
Cabergoline
Carteolol may increase the vasoconstricting activities of Cabergoline.
Cafedrine
Carteolol may increase the hypotensive activities of Cafedrine.
Calfactant
Carteolol may increase the bradycardic activities of Calfactant.
Canagliflozin
The risk or severity of adverse effects can be increased when Carteolol is combined with Canagliflozin.
Canagliflozin Anhydrous
The risk or severity of adverse effects can be increased when Carteolol is combined with Canagliflozin.
Candesartan
Carteolol may increase the hypotensive activities of Candesartan.
Candesartan Cilexetil
Carteolol may increase the hypotensive activities of Candesartan cilexetil.
Captopril
Carteolol may increase the hypotensive activities of Captopril.
Carbachol
The risk or severity of adverse effects can be increased when Carteolol is combined with Carbachol.
Carprofen
Carprofen may decrease the antihypertensive activities of Carteolol.
Carvedilol
Carteolol may increase the orthostatic hypotensive activities of Carvedilol.
Celecoxib
The metabolism of Carteolol can be decreased when combined with Celecoxib.
Celiprolol
Carteolol may decrease the bronchodilatory activities of Celiprolol.
Ceritinib
Carteolol may increase the bradycardic activities of Ceritinib.
Cevimeline
The risk or severity of adverse effects can be increased when Carteolol is combined with Cevimeline.
Chloroquine
The metabolism of Carteolol can be decreased when combined with Chloroquine.
Chlorothiazide
Carteolol may increase the hypotensive activities of Chlorothiazide.
Chlorpromazine
Carteolol may increase the orthostatic hypotensive activities of Chlorpromazine.
Chlorpropamide
Carteolol may increase the hypoglycemic activities of Chlorpropamide.
Chlorthalidone
Chlorthalidone may increase the hypotensive activities of Carteolol.
Cholecalciferol
The metabolism of Carteolol can be decreased when combined with Cholecalciferol.
Choline Magnesium Trisalicyclate
Choline magnesium trisalicylate may decrease the antihypertensive activities of Carteolol.
Cicletanine
Carteolol may increase the hypotensive activities of Cicletanine.
Cilazapril
Carteolol may increase the hypotensive activities of Cilazapril.
Cimetidine
The metabolism of Carteolol can be decreased when combined with Cimetidine.
Cinacalcet
The metabolism of Carteolol can be decreased when combined with Cinacalcet.
Citalopram
The metabolism of Carteolol can be decreased when combined with Citalopram.
Clemastine
The metabolism of Carteolol can be decreased when combined with Clemastine.
Clenbuterol
Carteolol may decrease the bronchodilatory activities of Clenbuterol.
Clevidipine
The risk or severity of adverse effects can be increased when Carteolol is combined with Clevidipine.
Clevidipine butyrate
The risk or severity of adverse effects can be increased when Carteolol is combined with Clevidipine.
Clobazam
The metabolism of Carteolol can be decreased when combined with Clobazam.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Carteolol.
Clomipramine
The metabolism of Carteolol can be decreased when combined with Clomipramine.
Clonidine
Clonidine may increase the atrioventricular blocking (AV block) activities of Carteolol.
Clonixin
Clonixin may decrease the antihypertensive activities of Carteolol.
Clotrimazole
The metabolism of Carteolol can be decreased when combined with Clotrimazole.
Clozapine
Carteolol may increase the orthostatic hypotensive activities of Clozapine.
Cobicistat
The serum concentration of Carteolol can be increased when it is combined with Cobicistat.
Cocaine
The metabolism of Carteolol can be decreased when combined with Cocaine.
Conivaptan
The risk or severity of adverse effects can be increased when Conivaptan is combined with Carteolol.
Crizotinib
Carteolol may increase the bradycardic activities of Crizotinib.
Cryptenamine
Carteolol may increase the hypotensive activities of Cryptenamine.
Curcumin
Curcumin may decrease the antihypertensive activities of Carteolol.
Cyclopenthiazide
Carteolol may increase the hypotensive activities of Cyclopenthiazide.
Cyclothiazide
Carteolol may increase the hypotensive activities of Cyclothiazide.
Dapagliflozin
The risk or severity of adverse effects can be increased when Carteolol is combined with Dapagliflozin.
Dapiprazole
Carteolol may increase the orthostatic hypotensive activities of Dapiprazole.
Darifenacin
The metabolism of Carteolol can be decreased when combined with Darifenacin.
Darunavir
The serum concentration of Carteolol can be increased when it is combined with Darunavir.
Debrisoquin
Debrisoquin may increase the hypotensive activities of Carteolol.
Delavirdine
The metabolism of Carteolol can be decreased when combined with Delavirdine.
Demecarium
Demecarium may increase the bradycardic activities of Carteolol.
Deserpidine
Carteolol may increase the hypotensive activities of Deserpidine.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Carteolol.
Desipramine
The metabolism of Carteolol can be decreased when combined with Desipramine.
Deslanoside
Carteolol may increase the bradycardic activities of Deslanoside.
Desvenlafaxine
The serum concentration of Carteolol can be increased when it is combined with Desvenlafaxine.
Dexmedetomidine
Dexmedetomidine may increase the atrioventricular blocking (AV block) activities of Carteolol.
Dextroamphetamine
Carteolol may increase the orthostatic hypotensive activities of Dextroamphetamine.
Diazoxide
Diazoxide may increase the hypotensive activities of Carteolol.
Dichlorphenamide
The risk or severity of adverse effects can be increased when Carteolol is combined with Diclofenamide.
Diclofenac
Diclofenac may decrease the antihypertensive activities of Carteolol.
Diflunisal
Diflunisal may decrease the antihypertensive activities of Carteolol.
Digitoxin
Carteolol may increase the bradycardic activities of Digitoxin.
Digoxin
Carteolol may increase the bradycardic activities of Digoxin.
Dihydralazine
Dihydralazine may increase the hypotensive activities of Carteolol.
Dihydroergotamine
Dihydroergotamine may increase the atrioventricular blocking (AV block) activities of Carteolol.
Diltiazem
Diltiazem may increase the hypotensive activities of Carteolol.
Dinutuximab
The risk or severity of adverse effects can be increased when Carteolol is combined with Dinutuximab.
Diphenhydramine
The metabolism of Carteolol can be decreased when combined with Diphenhydramine.
Dipivefrin
Carteolol may decrease the bronchodilatory activities of Dipivefrin.
Dipyridamole
Dipyridamole may increase the bradycardic activities of Carteolol.
Dipyrone
Metamizole may decrease the antihypertensive activities of Carteolol.
Disopyramide
Disopyramide may increase the bradycardic activities of Carteolol.
Distigmine
Distigmine may increase the bradycardic activities of Carteolol.
Dobutamine
Carteolol may decrease the bronchodilatory activities of Dobutamine.
Donepezil
Donepezil may increase the bradycardic activities of Carteolol.
Dorzolamide
Carteolol may increase the hypotensive activities of Dorzolamide.
Dothiepin
The metabolism of Carteolol can be decreased when combined with Dosulepin.
Doxazosin
Carteolol may increase the orthostatic hypotensive activities of Doxazosin.
Doxepin
Carteolol may increase the orthostatic hypotensive activities of Doxepin.
Dronedarone
Dronedarone may increase the bradycardic activities of Carteolol.
Droperidol
Carteolol may increase the orthostatic hypotensive activities of Droperidol.
Droxicam
Droxicam may decrease the antihypertensive activities of Carteolol.
Droxidopa
Carteolol may decrease the bronchodilatory activities of Droxidopa.
Duloxetine
Carteolol may increase the orthostatic hypotensive activities of Duloxetine.
Dyphylline
Carteolol may decrease the bronchodilatory activities of Dyphylline.
Echothiophate
Echothiophate may increase the bradycardic activities of Carteolol.
Edrophonium
Edrophonium may increase the bradycardic activities of Carteolol.
Eliglustat
The metabolism of Carteolol can be decreased when combined with Eliglustat.
Empagliflozin
The risk or severity of adverse effects can be increased when Carteolol is combined with Empagliflozin.
Enalapril
Carteolol may increase the hypotensive activities of Enalapril.
Enalaprilat
Carteolol may increase the hypotensive activities of Enalaprilat.
Enalaprilat Anhydrous
Carteolol may increase the hypotensive activities of Enalaprilat.
Epinephrine
Carteolol may decrease the bronchodilatory activities of Epinephrine.
Eplerenone
The risk or severity of adverse effects can be increased when Carteolol is combined with Eplerenone.
Epoprostenol
Carteolol may increase the hypotensive activities of Epoprostenol.
Eprosartan
Carteolol may increase the hypotensive activities of Eprosartan.
ergoloid mesylates, USP
Carteolol may increase the vasoconstricting activities of Ergoloid mesylate.
Ergonovine
Carteolol may increase the vasoconstricting activities of Ergonovine.
Ergotamine
Ergotamine may increase the atrioventricular blocking (AV block) activities of Carteolol.
Escitalopram
Carteolol may increase the orthostatic hypotensive activities of Escitalopram.
Esmolol
The risk or severity of adverse effects can be increased when Esmolol is combined with Carteolol.
Etanercept
Etanercept may decrease the antihypertensive activities of Carteolol.
Ethacrynate
The risk or severity of adverse effects can be increased when Carteolol is combined with Etacrynic acid.
Ethacrynic Acid
The risk or severity of adverse effects can be increased when Carteolol is combined with Etacrynic acid.
Etodolac
Etodolac may decrease the antihypertensive activities of Carteolol.
Etofenamate
Etofenamate may decrease the antihypertensive activities of Carteolol.
Etomidate
Etomidate may increase the atrioventricular blocking (AV block) activities of Carteolol.
Etoricoxib
Etoricoxib may decrease the antihypertensive activities of Carteolol.
Evening primrose oil
Evening primrose oil may decrease the antihypertensive activities of Carteolol.
Felbinac
Felbinac may decrease the antihypertensive activities of Carteolol.
Felodipine
Carteolol may increase the hypotensive activities of Felodipine.
Fenbufen
Fenbufen may decrease the antihypertensive activities of Carteolol.
Fenoldopam
Carteolol may increase the hypotensive activities of Fenoldopam.
Fenoprofen
Fenoprofen may decrease the antihypertensive activities of Carteolol.
Fenoterol
Carteolol may decrease the bronchodilatory activities of Fenoterol.
Fentanyl
Fentanyl may increase the bradycardic activities of Carteolol.
Ferulic Acid
Carteolol may increase the hypotensive activities of Ferulic acid.
Fesoterodine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Carteolol.
Fingolimod
Carteolol may increase the bradycardic activities of Fingolimod.
Floctafenine
The risk or severity of adverse effects can be increased when Carteolol is combined with Floctafenine.
Fluoxetine
The metabolism of Carteolol can be decreased when combined with Fluoxetine.
Flupenthixol
Carteolol may increase the orthostatic hypotensive activities of Flupentixol.
Fluphenazine
Fluphenazine may increase the hypotensive activities of Carteolol.
Flurbiprofen
Flurbiprofen may decrease the antihypertensive activities of Carteolol.
Fluvoxamine
The metabolism of Carteolol can be decreased when combined with Fluvoxamine.
Formoterol
Carteolol may decrease the bronchodilatory activities of Formoterol.
Fosinopril
Fosinopril may increase the hypotensive activities of Carteolol.
Fostamatinib
Fostamatinib may increase the antihypertensive activities of Carteolol.
Furazolidone
Furazolidone may increase the hypotensive activities of Carteolol.
Furosemide
The risk or severity of adverse effects can be increased when Carteolol is combined with Furosemide.
Galantamine
Galantamine may increase the bradycardic activities of Carteolol.
Gallamine Triethiodide
Gallamine Triethiodide may increase the bradycardic activities of Carteolol.
Ginkgo biloba extract
Ginkgo biloba may increase the bradycardic activities of Carteolol.
Glibornuride
Carteolol may increase the hypoglycemic activities of Glibornuride.
Gliclazide
Carteolol may increase the hypoglycemic activities of Gliclazide.
Glimepiride
Carteolol may increase the hypoglycemic activities of Glimepiride.
Glipizide
Carteolol may increase the hypoglycemic activities of Glipizide.
Gliquidone
Carteolol may increase the hypoglycemic activities of Gliquidone.
Glyburide
Carteolol may increase the hypoglycemic activities of Glyburide.
Guanabenz
Guanabenz may increase the atrioventricular blocking (AV block) activities of Carteolol.
Guanadrel
Guanadrel may increase the hypotensive activities of Carteolol.
Guanethidine
Carteolol may increase the hypotensive activities of Guanethidine.
Guanfacine
Guanfacine may increase the atrioventricular blocking (AV block) activities of Carteolol.
Haloperidol
The metabolism of Carteolol can be decreased when combined with Haloperidol.
Halothane
The risk or severity of adverse effects can be increased when Halothane is combined with Carteolol.
Hexobarbital
The serum concentration of Carteolol can be decreased when it is combined with Hexobarbital.
Hexoprenaline
Carteolol may decrease the bronchodilatory activities of Hexoprenaline.
Hydralazine
Hydralazine may increase the hypotensive activities of Carteolol.
Hydrochlorothiazide
Carteolol may increase the hypotensive activities of Hydrochlorothiazide.
Hydroflumethiazide
Carteolol may increase the hypotensive activities of Hydroflumethiazide.
Hydroxychloroquine
The metabolism of Carteolol can be decreased when combined with Hydroxychloroquine.
Ibuprofen
Ibuprofen may decrease the antihypertensive activities of Carteolol.
Icatibant
Icatibant may decrease the antihypertensive activities of Carteolol.
Iloperidone
Carteolol may increase the orthostatic hypotensive activities of Iloperidone.
Iloprost
The risk or severity of adverse effects can be increased when Iloprost is combined with Carteolol.
Imidapril
Carteolol may increase the hypotensive activities of Imidapril.
Imipramine
Carteolol may increase the orthostatic hypotensive activities of Imipramine.
Indacaterol
Carteolol may decrease the bronchodilatory activities of Indacaterol.
Indapamide
Carteolol may increase the hypotensive activities of Indapamide.
Indinavir
The metabolism of Carteolol can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Carteolol can be decreased when combined with Indinavir.
Indobufen
Indobufen may decrease the antihypertensive activities of Carteolol.
Indomethacin
Indomethacin may decrease the antihypertensive activities of Carteolol.
Indoramin
Carteolol may increase the orthostatic hypotensive activities of Indoramin.
insulin human, rDNA origin
Carteolol may increase the hypoglycemic activities of Insulin Human.
Insulin, Pork
Carteolol may increase the hypoglycemic activities of Insulin Pork.
Insulin, Regular, Pork
Carteolol may increase the hypoglycemic activities of Insulin Pork.
Iproniazid
Iproniazid may increase the hypotensive activities of Carteolol.
Irbesartan
Carteolol may increase the hypotensive activities of Irbesartan.
Isocarboxazid
Isocarboxazid may increase the hypotensive activities of Carteolol.
Isoetharine
Carteolol may decrease the bronchodilatory activities of Isoetarine.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Carteolol.
Isoflurophate
Isoflurophate may increase the bradycardic activities of Carteolol.
Isoniazid
The metabolism of Carteolol can be decreased when combined with Isoniazid.
Isoproterenol
Carteolol may decrease the bronchodilatory activities of Isoprenaline.
Isosorbide Dinitrate
The risk or severity of adverse effects can be increased when Carteolol is combined with Isosorbide Dinitrate.
Isosorbide Mononitrate
The risk or severity of adverse effects can be increased when Carteolol is combined with Isosorbide Mononitrate.
Isoxsuprine
The risk or severity of adverse effects can be increased when Carteolol is combined with Isoxsuprine.
Isradipine
Isradipine may increase the hypotensive activities of Carteolol.
Ivabradine
Carteolol may increase the bradycardic activities of Ivabradine.
Kebuzone
Kebuzone may decrease the antihypertensive activities of Carteolol.
Ketanserin
Ketanserin may increase the hypotensive activities of Carteolol.
Ketoconazole
The metabolism of Carteolol can be decreased when combined with Ketoconazole.
Ketoprofen
Ketoprofen may decrease the antihypertensive activities of Carteolol.
Ketorolac
Ketorolac may decrease the antihypertensive activities of Carteolol.
Labetalol
Carteolol may increase the orthostatic hypotensive activities of Labetalol.
Lacidipine
Carteolol may increase the hypotensive activities of Lacidipine.
Lacosamide
Carteolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.
Lanreotide
Carteolol may increase the bradycardic activities of Lanreotide.
Latanoprost
Carteolol may increase the hypotensive activities of Latanoprost.
Leflunomide
Leflunomide may decrease the antihypertensive activities of Carteolol.
Lercanidipine
Carteolol may increase the hypotensive activities of Lercanidipine.
Levalbuterol
Carteolol may decrease the bronchodilatory activities of Levosalbutamol.
Levobunolol
The risk or severity of adverse effects can be increased when Carteolol is combined with Levobunolol.
Levobupivacaine
The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Carteolol.
Levodopa
Carteolol may increase the orthostatic hypotensive activities of Levodopa.
Levomilnacipran
The serum concentration of Carteolol can be increased when it is combined with Levomilnacipran.
Levonordefrin
Levonordefrin may increase the atrioventricular blocking (AV block) activities of Carteolol.
Levosimendan
The risk or severity of adverse effects can be increased when Levosimendan is combined with Carteolol.
Lidocaine
The serum concentration of Lidocaine can be increased when it is combined with Carteolol.
Limonene, (+)-
(4R)-limonene may decrease the antihypertensive activities of Carteolol.
Lisdexamfetamine
Carteolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.
Lisdexamfetamine Dimesylate
Carteolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.
Lisinopril
Carteolol may increase the hypotensive activities of Lisinopril.
Lisinopril Anhydrous
Carteolol may increase the hypotensive activities of Lisinopril.
Lobeline
The risk or severity of adverse effects can be increased when Carteolol is combined with Lobeline.
Lofexidine
Lofexidine may increase the atrioventricular blocking (AV block) activities of Carteolol.
Lopinavir
The metabolism of Carteolol can be decreased when combined with Lopinavir.
Lorcaserin
The metabolism of Carteolol can be decreased when combined with Lorcaserin.
Lornoxicam
Lornoxicam may decrease the antihypertensive activities of Carteolol.
Losartan
Carteolol may increase the hypotensive activities of Losartan.
Loxoprofen
Loxoprofen may decrease the antihypertensive activities of Carteolol.
Lucinactant
Carteolol may increase the bradycardic activities of Lucinactant.
Lumefantrine
The metabolism of Carteolol can be decreased when combined with Lumefantrine.
Macitentan
Carteolol may increase the hypotensive activities of Macitentan.
Magnesium Salicylate
Magnesium salicylate may decrease the antihypertensive activities of Carteolol.
Malathion
Malathion may increase the bradycardic activities of Carteolol.
Manidipine
Carteolol may increase the hypotensive activities of Manidipine.
Mannitol
The risk or severity of adverse effects can be increased when Carteolol is combined with Mannitol.
Masoprocol
Masoprocol may decrease the antihypertensive activities of Carteolol.
Mecamylamine
Mecamylamine may increase the hypotensive activities of Carteolol.
Meclofenamate
Meclofenamic acid may decrease the antihypertensive activities of Carteolol.
Meclofenamic Acid
Meclofenamic acid may decrease the antihypertensive activities of Carteolol.
Mefenamic Acid
Mefenamic acid may decrease the antihypertensive activities of Carteolol.
Mefloquine
Mefloquine may increase the bradycardic activities of Carteolol.
Meloxicam
Meloxicam may decrease the antihypertensive activities of Carteolol.
Memantine
Memantine may increase the bradycardic activities of Carteolol.
Mephobarbital
The serum concentration of Carteolol can be decreased when it is combined with Methylphenobarbital.
Mepirodipine
Carteolol may increase the antihypertensive activities of Barnidipine.
Mepivacaine
The serum concentration of Mepivacaine can be increased when it is combined with Carteolol.
Mesalamine
Mesalazine may decrease the antihypertensive activities of Carteolol.
Mesoridazine
Mesoridazine may increase the hypotensive activities of Carteolol.
Metaproterenol
Carteolol may decrease the bronchodilatory activities of Orciprenaline.
Methacholine
Carteolol may increase the bronchoconstrictory activities of Methacholine.
Methadone
The metabolism of Carteolol can be decreased when combined with Methadone.
Methamphetamine
Methamphetamine may increase the atrioventricular blocking (AV block) activities of Carteolol.
Methazolamide
The risk or severity of adverse effects can be increased when Carteolol is combined with Methazolamide.
Methohexital
The serum concentration of Carteolol can be decreased when it is combined with Methohexital.
Methotrimeprazine
The metabolism of Carteolol can be decreased when combined with Methotrimeprazine.
Methyclothiazide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carteolol.
Methyldopa
Methyldopa may increase the atrioventricular blocking (AV block) activities of Carteolol.
METHYLDOPA ANHYDROUS
Methyldopa may increase the atrioventricular blocking (AV block) activities of Carteolol.
Methylene blue
Methylene blue may increase the hypotensive activities of Carteolol.
METHYLEPHEDRINE, DL-
DL-Methylephedrine may increase the atrioventricular blocking (AV block) activities of Carteolol.
Methylergonovine
Carteolol may increase the vasoconstricting activities of Methylergometrine.
Methylphenidate
Methylphenidate may decrease the antihypertensive activities of Carteolol.
Metipranolol
Carteolol may increase the hypotensive activities of Metipranolol.
Metoclopramide
Metoclopramide may increase the bradycardic activities of Carteolol.
Metolazone
Carteolol may increase the hypotensive activities of Metolazone.
Metoprolol
The serum concentration of Metoprolol can be increased when it is combined with Carteolol.
Metyrosine
Carteolol may increase the hypotensive activities of Metyrosine.
Mibefradil
Carteolol may increase the hypotensive activities of Mibefradil.
Midodrine
Carteolol may increase the bradycardic activities of Midodrine.
Midostaurin
The metabolism of Carteolol can be decreased when combined with Midostaurin.
Milnacipran
The serum concentration of Carteolol can be increased when it is combined with Milnacipran.
Minaprine
Minaprine may increase the bradycardic activities of Carteolol.
Minoxidil
Minoxidil may increase the hypotensive activities of Carteolol.
Mirabegron
The metabolism of Carteolol can be decreased when combined with Mirabegron.
Moclobemide
Moclobemide may increase the hypotensive activities of Carteolol.
Moexipril
Carteolol may increase the hypotensive activities of Moexipril.
Molsidomine
Molsidomine may increase the hypotensive activities of Carteolol.
Moricizine
Moricizine may increase the hypotensive activities of Carteolol.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Carteolol.
Moxonidine
Moxonidine may increase the atrioventricular blocking (AV block) activities of Carteolol.
MYCOPHENOLATE
Mycophenolic acid may decrease the antihypertensive activities of Carteolol.
Mycophenolate Mofetil
Mycophenolate mofetil may decrease the antihypertensive activities of Carteolol.
Mycophenolic Acid
Mycophenolic acid may decrease the antihypertensive activities of Carteolol.
N-methylephedrine
DL-Methylephedrine may increase the atrioventricular blocking (AV block) activities of Carteolol.
Nabilone
The risk or severity of adverse effects can be increased when Nabilone is combined with Carteolol.
Nabumetone
Nabumetone may decrease the antihypertensive activities of Carteolol.
Nadolol
Carteolol may increase the hypotensive activities of Nadolol.
Naftifine
Naftifine may decrease the antihypertensive activities of Carteolol.
Naphazoline
Naphazoline may increase the atrioventricular blocking (AV block) activities of Carteolol.
Naproxen
Naproxen may decrease the antihypertensive activities of Carteolol.
Nebivolol
Carteolol may increase the hypotensive activities of Nebivolol.
Nefazodone
Carteolol may increase the orthostatic hypotensive activities of Nefazodone.
Neostigmine
Neostigmine may increase the bradycardic activities of Carteolol.
Nepafenac
Nepafenac may decrease the antihypertensive activities of Carteolol.
Nesiritide
The risk or severity of adverse effects can be increased when Carteolol is combined with Nesiritide.
Nevirapine
The metabolism of Carteolol can be decreased when combined with Nevirapine.
Nialamide
Nialamide may increase the hypotensive activities of Carteolol.
Nicardipine
Carteolol may increase the orthostatic hypotensive activities of Nicardipine.
Nicergoline
Carteolol may increase the orthostatic hypotensive activities of Nicergoline.
Nicorandil
Nicorandil may increase the hypotensive activities of Carteolol.
Nicotine
The risk or severity of adverse effects can be increased when Carteolol is combined with Nicotine.
Nicotine Polacrilex
The risk or severity of adverse effects can be increased when Carteolol is combined with Nicotine.
Nifedipine
The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Carteolol.
Niflumic Acid
Niflumic Acid may decrease the antihypertensive activities of Carteolol.
Nilotinib
The metabolism of Carteolol can be decreased when combined with Nilotinib.
Nilvadipine
Carteolol may increase the hypotensive activities of Nilvadipine.
Nimesulide
Nimesulide may decrease the antihypertensive activities of Carteolol.
Nimodipine
Nimodipine may increase the hypotensive activities of Carteolol.
Nisoldipine
Nisoldipine may increase the hypotensive activities of Carteolol.
Nitrendipine
Carteolol may increase the hypotensive activities of Nitrendipine.
Nitric Oxide
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Carteolol.
Nitroglycerin
The risk or severity of adverse effects can be increased when Carteolol is combined with Nitroglycerin.
Nitroprusside
Nitroprusside may increase the hypotensive activities of Carteolol.
Norepinephrine
Carteolol may decrease the bronchodilatory activities of Norepinephrine.
Nortriptyline
Carteolol may increase the orthostatic hypotensive activities of Nortriptyline.
O-PHENANTHROLINE
1,10-Phenanthroline may increase the bradycardic activities of Carteolol.
Obinutuzumab
Carteolol may increase the hypotensive activities of Obinutuzumab.
Octreotide
Octreotide may increase the bradycardic activities of Carteolol.
Oenothera biennis seed extract
Evening primrose oil may decrease the antihypertensive activities of Carteolol.
Olanzapine
Carteolol may increase the orthostatic hypotensive activities of Olanzapine.
Olmesartan
Olmesartan may increase the hypotensive activities of Carteolol.
Olodaterol
Carteolol may decrease the bronchodilatory activities of Olodaterol.
Olopatadine
Olopatadine may decrease the antihypertensive activities of Carteolol.
Olsalazine
Olsalazine may decrease the antihypertensive activities of Carteolol.
Ouabain
Carteolol may increase the bradycardic activities of Ouabain.
Ovine Digoxin Immune Fab
Carteolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).
Oxaprozin
Oxaprozin may decrease the antihypertensive activities of Carteolol.
Oxprenolol
Carteolol may increase the hypotensive activities of Oxprenolol.
Oxymetazoline
Oxymetazoline may increase the atrioventricular blocking (AV block) activities of Carteolol.
Oxyphenbutazone
Oxyphenbutazone may decrease the antihypertensive activities of Carteolol.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Carteolol.
Paliperidone
Paliperidone may increase the atrioventricular blocking (AV block) activities of Carteolol.
Palmidrol
Palmidrol may decrease the antihypertensive activities of Carteolol.
Panobinostat
The serum concentration of Carteolol can be increased when it is combined with Panobinostat.
Papaverine
The risk or severity of adverse effects can be increased when Carteolol is combined with Papaverine.
Parecoxib
Parecoxib may decrease the antihypertensive activities of Carteolol.
Paregoric
The risk or severity of adverse effects can be increased when Morphine is combined with Carteolol.
Pargyline
Pargyline may increase the hypotensive activities of Carteolol.
Paroxetine
The metabolism of Carteolol can be decreased when combined with Paroxetine.
Parthenolide
Parthenolide may decrease the antihypertensive activities of Carteolol.
Pasireotide
Carteolol may increase the bradycardic activities of Pasireotide.
Peginterferon Alfa-2b
The serum concentration of Carteolol can be decreased when it is combined with Peginterferon alfa-2b.
Penbutolol
Carteolol may increase the hypotensive activities of Penbutolol.
Pentobarbital
The serum concentration of Carteolol can be decreased when it is combined with Pentobarbital.
Pentoxifylline
Pentoxifylline may increase the hypotensive activities of Carteolol.
Perazine
Perazine may increase the hypotensive activities of Carteolol.
Pergolide
Pergolide may increase the atrioventricular blocking (AV block) activities of Carteolol.
Periciazine
Carteolol may increase the orthostatic hypotensive activities of Propericiazine.
Perindopril
Carteolol may increase the hypotensive activities of Perindopril.
Perphenazine
Perphenazine may increase the hypotensive activities of Carteolol.
Phenelzine
Phenelzine may increase the hypotensive activities of Carteolol.
Phenobarbital
The serum concentration of Carteolol can be decreased when it is combined with Phenobarbital.
Phenoxybenzamine
Carteolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.
Phentolamine
Carteolol may increase the orthostatic hypotensive activities of Phentolamine.
Phentolamine Mesylate
Carteolol may increase the orthostatic hypotensive activities of Phentolamine.
Phenylbutazone
Phenylbutazone may decrease the antihypertensive activities of Carteolol.
Phenylpropanolamine
Carteolol may decrease the bronchodilatory activities of Phenylpropanolamine.
Physostigmine
Physostigmine may increase the bradycardic activities of Carteolol.
Pilocarpine
The risk or severity of adverse effects can be increased when Carteolol is combined with Pilocarpine.
Pimecrolimus
Pimecrolimus may decrease the antihypertensive activities of Carteolol.
Pinacidil
Pinacidil may increase the hypotensive activities of Carteolol.
Pindolol
Carteolol may increase the hypotensive activities of Pindolol.
Pipamperone
The risk or severity of adverse effects can be increased when Pipamperone is combined with Carteolol.
Pirbuterol
Carteolol may decrease the bronchodilatory activities of Pirbuterol.
Pirfenidone
Pirfenidone may decrease the antihypertensive activities of Carteolol.
Piroxicam
Piroxicam may decrease the antihypertensive activities of Carteolol.
Piroxicam-Beta-Cyclodextrin
Piroxicam may decrease the antihypertensive activities of Carteolol.
Pizotyline
Carteolol may increase the orthostatic hypotensive activities of Pizotifen.
Polythiazide
Carteolol may increase the hypotensive activities of Polythiazide.
Poractant alfa
Carteolol may increase the bradycardic activities of Poractant alfa.
Pramipexole
The risk or severity of adverse effects can be increased when Pramipexole is combined with Carteolol.
Prazosin
Carteolol may increase the orthostatic hypotensive activities of Prazosin.
Primaquine
The metabolism of Carteolol can be decreased when combined with Primaquine.
Primidone
The serum concentration of Carteolol can be decreased when it is combined with Primidone.
Procaine
Procaine may increase the hypotensive activities of Carteolol.
Procarbazine
Procarbazine may increase the hypotensive activities of Carteolol.
Procaterol
Carteolol may decrease the bronchodilatory activities of Procaterol.
Prochlorperazine
Prochlorperazine may increase the hypotensive activities of Carteolol.
Promazine
Carteolol may increase the orthostatic hypotensive activities of Promazine.
Promethazine
Promethazine may increase the hypotensive activities of Carteolol.
Propafenone
The serum concentration of Carteolol can be increased when it is combined with Propafenone.
Propiomazine
Carteolol may increase the orthostatic hypotensive activities of Propiomazine.
Propiverine
Carteolol may increase the orthostatic hypotensive activities of Propiverine.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Carteolol.
Propranolol
Carteolol may increase the hypotensive activities of Propranolol.
Proscillaridin
Carteolol may increase the bradycardic activities of Proscillaridin.
Pseudoephedrine
Pseudoephedrine may increase the atrioventricular blocking (AV block) activities of Carteolol.
Pyridostigmine
Pyridostigmine may increase the bradycardic activities of Carteolol.
Pyridostigmine Bromide
Pyridostigmine may increase the bradycardic activities of Carteolol.
Quetiapine
Carteolol may increase the orthostatic hypotensive activities of Quetiapine.
Quetiapine fumarate
Carteolol may increase the orthostatic hypotensive activities of Quetiapine.
Quinapril
Carteolol may increase the hypotensive activities of Quinapril.
Quinidine
The metabolism of Carteolol can be decreased when combined with Quinidine.
Quinine
The metabolism of Carteolol can be decreased when combined with Quinine.
Racepinephrine
Carteolol may decrease the bronchodilatory activities of Racepinephrine.
Ramipril
Ramipril may increase the hypotensive activities of Carteolol.
Ranolazine
The metabolism of Carteolol can be decreased when combined with Ranolazine.
Rasagiline
Rasagiline may increase the hypotensive activities of Carteolol.
Regorafenib
Regorafenib may increase the bradycardic activities of Carteolol.
Regular Insulin, Human
Carteolol may increase the hypoglycemic activities of Insulin Human.
Remifentanil
Remifentanil may increase the bradycardic activities of Carteolol.
Rescinnamine
Carteolol may increase the hypotensive activities of Rescinnamine.
Reserpine
Reserpine may increase the hypotensive activities of Carteolol.
Resveratrol
Resveratrol may decrease the antihypertensive activities of Carteolol.
Rifampin
The serum concentration of Carteolol can be decreased when it is combined with Rifampicin.
Rifapentine
The serum concentration of Carteolol can be decreased when it is combined with Rifapentine.
Rifaximin
The serum concentration of Carteolol can be decreased when it is combined with Rifaximin.
Rilmenidine
Rilmenidine may increase the hypotensive activities of Carteolol.
Riociguat
Carteolol may increase the hypotensive activities of Riociguat.
Risperidone
Carteolol may increase the hypotensive activities of Risperidone.
Ritodrine
Carteolol may decrease the bronchodilatory activities of Ritodrine.
Ritonavir
The metabolism of Carteolol can be decreased when combined with Ritonavir.
Rituximab
Carteolol may increase the hypotensive activities of Rituximab.
Rivastigmine
Carteolol may increase the bradycardic activities of Rivastigmine.
Rofecoxib
Rofecoxib may decrease the antihypertensive activities of Carteolol.
Rolapitant
The metabolism of Carteolol can be decreased when combined with Rolapitant.
Ropinirole
Ropinirole may increase the atrioventricular blocking (AV block) activities of Carteolol.
Ropivacaine
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Carteolol.
Rotigotine
The risk or severity of adverse effects can be increased when Rotigotine is combined with Carteolol.
Rucaparib
The metabolism of Carteolol can be decreased when combined with Rucaparib.
Ruxolitinib
Ruxolitinib may increase the bradycardic activities of Carteolol.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Carteolol.
Salicylamide
Salicylamide may decrease the antihypertensive activities of Carteolol.
Salicylic Acid
Salicylic acid may decrease the antihypertensive activities of Carteolol.
Salmeterol
Carteolol may decrease the bronchodilatory activities of Salmeterol.
Salsalate
Salsalate may decrease the antihypertensive activities of Carteolol.
Secobarbital
The serum concentration of Carteolol can be decreased when it is combined with Secobarbital.
Selegiline
Selegiline may increase the hypotensive activities of Carteolol.
Selexipag
Carteolol may increase the hypotensive activities of Selexipag.
Serratiopeptidase
Serrapeptase may decrease the antihypertensive activities of Carteolol.
Sertraline
The metabolism of Carteolol can be decreased when combined with Sertraline.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Carteolol.
Sildenafil
Sildenafil may increase the antihypertensive activities of Carteolol.
Silodosin
Carteolol may increase the orthostatic hypotensive activities of Silodosin.
Sotalol
The risk or severity of adverse effects can be increased when Sotalol is combined with Carteolol.
Spirapril
Carteolol may increase the hypotensive activities of Spirapril.
Spironolactone
The risk or severity of adverse effects can be increased when Spironolactone is combined with Carteolol.
Streptokinase
The risk or severity of adverse effects can be increased when Streptokinase is combined with Carteolol.
Sufentanil
Sufentanil may increase the bradycardic activities of Carteolol.
Sulfasalazine
Sulfasalazine may decrease the antihypertensive activities of Carteolol.
Sulindac
Sulindac may decrease the antihypertensive activities of Carteolol.
Suprofen
Suprofen may decrease the antihypertensive activities of Carteolol.
Tacrine
Tacrine may increase the bradycardic activities of Carteolol.
Tadalafil
Tadalafil may increase the antihypertensive activities of Carteolol.
Talinolol
Carteolol may increase the hypotensive activities of Talinolol.
Tamsulosin
Carteolol may increase the orthostatic hypotensive activities of Tamsulosin.
Telmisartan
Carteolol may increase the hypotensive activities of Telmisartan.
Tenoxicam
Tenoxicam may decrease the antihypertensive activities of Carteolol.
Terazosin
Carteolol may increase the orthostatic hypotensive activities of Terazosin.
Terbinafine
The metabolism of Carteolol can be decreased when combined with Terbinafine.
Terbutaline
Carteolol may decrease the bronchodilatory activities of Terbutaline.
Terbutaline Sulfate
Carteolol may decrease the bronchodilatory activities of Terbutaline.
Teriflunomide
Teriflunomide may decrease the antihypertensive activities of Carteolol.
Terlipressin
Carteolol may increase the hypotensive activities of Terlipressin.
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Carteolol.
Theodrenaline
Carteolol may increase the hypotensive activities of Theodrenaline.
Theophylline
Carteolol may decrease the bronchodilatory activities of Theophylline.
Theophylline anhydrous
Carteolol may decrease the bronchodilatory activities of Theophylline.
Thiamylal
The serum concentration of Carteolol can be decreased when it is combined with Thiamylal.
Thiethylperazine
Thiethylperazine may increase the hypotensive activities of Carteolol.
Thiopental
The serum concentration of Carteolol can be decreased when it is combined with Thiopental.
Thiopental Sodium
The serum concentration of Carteolol can be decreased when it is combined with Thiopental.
Thioproperazine
Carteolol may increase the orthostatic hypotensive activities of Thioproperazine.
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Carteolol.
Tiaprofenic Acid
Tiaprofenic acid may decrease the antihypertensive activities of Carteolol.
Tibolone
Carteolol may increase the hypotensive activities of Tibolone.
Ticlopidine
The metabolism of Carteolol can be decreased when combined with Ticlopidine.
Timolol
Timolol may increase the hypotensive activities of Carteolol.
Timolol Anhydrous
Timolol may increase the hypotensive activities of Carteolol.
Tipranavir
The metabolism of Carteolol can be decreased when combined with Tipranavir.
Tizanidine
Tizanidine may increase the atrioventricular blocking (AV block) activities of Carteolol.
Tofacitinib
Tofacitinib may increase the bradycardic activities of Carteolol.
Tolazamide
Carteolol may increase the hypoglycemic activities of Tolazamide.
Tolazoline
Carteolol may increase the orthostatic hypotensive activities of Tolazoline.
Tolbutamide
Carteolol may increase the hypoglycemic activities of Tolbutamide.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Carteolol.
Tolfenamic Acid
Tolfenamic Acid may decrease the antihypertensive activities of Carteolol.
Tolmetin
Tolmetin may decrease the antihypertensive activities of Carteolol.
Toloxatone
Toloxatone may increase the hypotensive activities of Carteolol.
Torsemide
Torasemide may increase the hypotensive activities of Carteolol.
Trandolapril
Trandolapril may increase the hypotensive activities of Carteolol.
Tranilast
Tranilast may decrease the antihypertensive activities of Carteolol.
Tranylcypromine
The metabolism of Carteolol can be decreased when combined with Tranylcypromine.
Travoprost
Travoprost may increase the hypotensive activities of Carteolol.
Trazodone
Carteolol may increase the orthostatic hypotensive activities of Trazodone.
Treprostinil
Treprostinil may increase the hypotensive activities of Carteolol.
Tretinoin
The risk or severity of adverse effects can be increased when Tretinoin is combined with Carteolol.
Triamterene
The risk or severity of adverse effects can be increased when Triamterene is combined with Carteolol.
Tribenoside
Tribenoside may decrease the antihypertensive activities of Carteolol.
Trichlormethiazide
Carteolol may increase the hypotensive activities of Trichlormethiazide.
Trifluoperazine
Carteolol may increase the orthostatic hypotensive activities of Trifluoperazine.
Triflupromazine
Triflupromazine may increase the hypotensive activities of Carteolol.
Trimeprazine
Alimemazine may increase the hypotensive activities of Carteolol.
Trimethaphan
Trimethaphan may increase the hypotensive activities of Carteolol.
Trimipramine
Carteolol may increase the orthostatic hypotensive activities of Trimipramine.
Tubocurarine
Tubocurarine may increase the bradycardic activities of Carteolol.
Tyrothricin
Tyrothricin may increase the bradycardic activities of Carteolol.
UNOPROSTONE
Carteolol may increase the hypotensive activities of Unoprostone.
Urapidil
Carteolol may increase the orthostatic hypotensive activities of Urapidil.
Valdecoxib
Valdecoxib may decrease the antihypertensive activities of Carteolol.
Valsartan
Valsartan may increase the hypotensive activities of Carteolol.
Vardenafil
Vardenafil may increase the antihypertensive activities of Carteolol.
Varenicline
The risk or severity of adverse effects can be increased when Carteolol is combined with Varenicline.
Venlafaxine
The metabolism of Carteolol can be decreased when combined with Venlafaxine.
Verapamil
Carteolol may increase the orthostatic hypotensive activities of Verapamil.
Vilanterol
Carteolol may decrease the bronchodilatory activities of Vilanterol.
Vincamine
Carteolol may increase the hypotensive activities of Vincamine.
Vinpocetine
Carteolol may increase the hypotensive activities of Vinpocetine.
Xylazine
Xylazine may increase the atrioventricular blocking (AV block) activities of Carteolol.
Xylometazoline
Xylometazoline may increase the atrioventricular blocking (AV block) activities of Carteolol.
Yohimbine
Yohimbine may decrease the antihypertensive activities of Carteolol.
Zileuton
Zileuton may decrease the antihypertensive activities of Carteolol.
Ziprasidone
Carteolol may increase the orthostatic hypotensive activities of Ziprasidone.
Zofenopril
Carteolol may increase the hypotensive activities of Zofenopril.
Zomepirac
Zomepirac may decrease the antihypertensive activities of Carteolol.
Zuclopenthixol
Carteolol may increase the orthostatic hypotensive activities of Zuclopenthixol.
